First Trust Nasdaq Pharmaceuticals ETF FTXH
44.37 USD -0.02 (-0.05%)
At closeNov 10, 2026, 4:00 PM EST
44.39 +0.02 +0.05%
After hours · Nov 10, 4:00 PM ET
43.95 Day range 44.44
30.40 52-week range 44.86
- YTD
- +34.70%
- 1 year
- +45.95%
News
zacks.com Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
zacks.com Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)? Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the First Trust NASDAQ Pharmaceuticals ETF (FTXH), a passively managed exchange traded fund…
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
zacks.com Is First Trust NASDAQ Pharmaceuticals ETF (FTXH) a Strong ETF Right Now? The First Trust NASDAQ Pharmaceuticals ETF (FTXH) was launched on 09/20/2016, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
zacks.com Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)? Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the First Trust NASDAQ Pharmaceuticals ETF (FTXH) is a passively managed exchange traded fund launched on…
reuters.com Trump to announce discount drug pricing expansion, White House official says U.S. President Donald Trump will announce a dramatic expansion of TrumpRx.gov, a government-backed website offering discounted prescription drugs under his administration's pricing deal, on Monday,…
marketwatch.com Could pressure to make money faster kill the next lifesaving pill? When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
benzinga.com What's Going On With Bristol-Myers Squibb Stock Today? Bristol Myers stock is volatile ahead of earnings as investors weighed its expanded OXB manufacturing deal and recent bullish analyst commentary.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
zacks.com Pharma ETF (FTXH) Hits New 52-Week High Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.
benzinga.com Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
fastcompany.com Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1 President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks…
zacks.com Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
zacks.com A Look at Pharma ETFs After Strong Q1 Earnings Many pharma bigwigs reported solid results, with some beating on earnings or revenues or both.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations A federal court blocked NIH's policy capping indirect cost rates on research grants, ruling it unlawful. The decision safeguards billions in funding and ongoing clinical trials.
benzinga.com Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.
benzinga.com FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
zacks.com Pharma ETFs in Focus Post Solid Q2 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
benzinga.com Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local…
zacks.com A Look at Pharma ETFs Post Q1 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
zacks.com A Look at Pharma ETFs After Q4 Earnings The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs…
zacks.com Pharma ETFs in Focus Post Q3 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
zacks.com Pharma ETFs in Focus Post Q2 Earnings Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
zacks.com 5 ETFs to Buy on JNJ's Q2 Earnings Strength Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It topped the revenue estimate as well as lifted the full-year outlook.
zacks.com Biotech ETFs in Focus on Covid Vaccines' Fall Rollout The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
zacks.com Pharma ETFs Gain Post Q1 Earnings Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
seekingalpha.com Can Health Care Stocks Outperform Again In 2023? How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.